Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dustin Goetz

Anesthesiology Bismarck, ND Medical Doctor

NPI 1598177891 CMS profile 1035151

202 E Greenfield Ln Ste 100, Bismarck, ND 58503

Open in the dashboard

General payments

$7,734

107 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dustin Goetz of Bismarck, ND is reported in the CMS Open Payments database as having received $7,734 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $276 7
2024 General $165 7
2023 General $133 8
2022 General $1,452 13
2021 General $3,605 26
2020 General $1,401 29
2019 General $701 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dustin Goetz
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Dustin Goetz were reported at $276. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Dustin Goetz Anesthesiology median Middle half National median
2019 $701 $72 $23–$151 $163
2020 $1,401 $36 $17–$120 $114
2021 $3,605 $49 $21–$135 $132
2022 $1,452 $52 $22–$144 $149
2023 $133 $53 $23–$143 $160
2024 $165 $55 $25–$150 $164
2025 $276 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,073 36 payments
  2. Medtronic USA, Inc. $1,546 30 payments
  3. Abbott Laboratories $1,344 10 payments
  4. Nalu Medical, Inc. $1,141 5 payments
  5. MML US, Inc. $1,104 5 payments
  6. Nevro Corp. $239 4 payments
  7. Allergan Inc. $93 6 payments
  8. Stimwave Technologies Incorporated $68 5 payments
  9. Ethicon US, LLC $36 1 payment
  10. Omeros Corporation $27 2 payments
  11. Other $62 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,754 17 payments
  2. Food and Beverage $2,855 89 payments
  3. Consulting Fee $125 1 payment
Products named General payments · program years 2019–2025
  1. Superion Indirect Decompression System $1,376 8 payments
  2. Proclaim IPG $1,275 7 payments
  3. Nalu Neurostimulation System $1,141 5 payments
  4. SYNCHROMED $1,137 12 payments
  5. ReActiv8 $1,104 5 payments
  6. INTELLIS $355 14 payments
  7. Senza Spinal Cord Stimulation System $211 3 payments
  8. GENERAL PAIN MANAGEMENT $187 4 payments
  9. WaveWriter Alpha Prime 16 $90 5 payments
  10. SPECTRA WAVEWRITER $70 1 payment
  11. Other $735 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

14

Median for Pain Management: 951

Drug cost

$130

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 14 $130

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$79,554

Medicare's payments for the services billed

Medicare patients

574

Average age 74

Services billed

1,130

316 women, 258 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Diabetes 26%
Ischemic heart disease 24%
Depression 22%
Osteoporosis 22%
Chronic kidney disease 19%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record